NSCLC, NON-SMALL-CELL LUNG CARCINOMA
Clinical trials for NSCLC, NON-SMALL-CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NSCLC, NON-SMALL-CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NSCLC, NON-SMALL-CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to destroy lung Cancer's fuel source
Disease control OngoingThis early-phase study tests a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives non-small cell lung cancer. About 33 adults with advanced or spreading lung cancer who have already tried other treatments will receive the drug to see if it is sa…
Matched conditions: NSCLC, NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Russian lung cancer patients under the microscope: durvalumab in daily practice
Knowledge-focused OngoingThis study looks at how the drug durvalumab works in everyday medical practice for people with a certain type of advanced lung cancer (NSCLC) that cannot be removed by surgery. Researchers will track about 250 patients in Russia to see how safe the drug is and how long people sta…
Matched conditions: NSCLC, NON-SMALL-CELL LUNG CARCINOMA
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 17, 2026 02:01 UTC